Ethris and Munster University Hospital Receive ZIM Grant for Rare Pulmonary Disease Research

04:00 EDT 1 Oct 2019 | Businesswire
This article has expired, however you can still download the PDF.
Collaboration with Prof. Heymut Omran’s laboratory aimed at studying the impact of Ethris’ therapeutic mRNA strategy on primary ciliary dyskinesia Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, announce...

Other Sources for this Article

For more information:
Ethris GmbH
Dagmar Ackerknecht
+49-(0)89-8955-788 10

Media requests:
Mario Brkulj or Amanda Houlihan
+49 175 5711562 or +1 781-235-3060


More From BioPortfolio on "Ethris and Munster University Hospital Receive ZIM Grant for Rare Pulmonary Disease Research"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...